2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
COVID-19 and the need for remote clinical trials
Whilst the COVID pandemic has dealt a cruel blow to current Parkinson’s research efforts, it has served as an opportunity for innovation and improvement, and this is particularly so in the way some clinical trials are being organised.
More data from the ‘Blue Rockers’
BlueRock Therapeutics has published two preclinical research reports outlining the cell culturing method that they are taking into clinical trials.
Parkinson’s and pesticides
Much of our focus is on treatments, but treatments are only part of the story. A vital step for Cure Parkinson’s is to stop people from getting Parkinson’s in the first place. Read more about taking action against pesticide use.
GDNF – A new chapter
We welcome the news of further investment in GDNF (Glial Cell-Line Derived Neurotrophic Factor) by Parkinson’s UK.
Ambroxol – new real-world data
Ambroxol is a cough medication that Cure Parkinson’s is repurposing for potential use in treating Parkinson’s, and recently published data provides further support for this pioneering new study.